Belmont Center for Comprehensive Treatment

Philadelphia, Pennsylvania 19131-1689

0 studies enrolling now · 13 studies all time

What they study most

Alzheimer's Disease, Bipolar Disorder, Depression, Major Depressive Disorder, Psychosis, Psychotic Depression, Schizoaffective Disorder, Schizophrenia, Severe Major Depression With Psychotic Features, Smoking Cessation

Studies at this site

• A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features — Stopped early
• Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease — Completed
• Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders. — Completed
• Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders — Completed
• Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder — Completed
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• CATIE- Schizophrenia Trial — Completed
• Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder. — Completed
• Switching to Iloperidone From Other Antipsychotics in Schizophrenia — Completed
• Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia — Completed